ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Accepts sBLA Filing of Soliris® as a Potential Treatment for Patients with Refractory Generalize
March 09, 2017Alexion Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental Biologics License Application (sBLA) to extend the indication for Soliris® (eculizumab) as a potential treatment for
Pharma Sources Insight January 2025
